A	B	C
1	Main
2		Brand Name	Opdivo, fka BMS-936558
3		Generic Name
4		Indication	Cancer
5		Mechanism	Anti-PD-1 Antibody
6		Economics	Ono has Japanese rights.
7		Clinical Trials
8			Phase III NSCLC versus Taxotere n=264
9			Primary endpoint: ORR/OS
10
11			Phase I "Study 301" n=296 in all cancers
12			n=104 melanoma, n=122 NSCLC, n=34 RCC, n=17 CRPC, n=19 CRC
13			Dose ranging from 0.3mg/kg to 10.0mg/kg
14			9/52 response rate in melanoma
15			2/17 in RCC
16			5/49 in NSCLC
17			1/17 in ovarian cancer
18			8/16 responses lasted longer than 1 year